Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (10): 858-863.doi: 10.35541/cjd.20220030

• Original Articles • Previous Articles     Next Articles

Effect of azacitidine on HOXA9 gene expression and biological behaviors of A375 melanoma cells

Li Tingting, Zhao Juan, Wang Peng, Liu Dongmei, Kang Xiaojing   

  1. Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research(XJYS1707), Urumqi 830001, China
  • Received:2022-01-14 Revised:2022-06-29 Online:2022-10-15 Published:2022-10-08
  • Contact: Kang Xiaojing E-mail:kangxiaojing163@163.com
  • Supported by:
    Natural Science Foundation of Xinjiang Uygur Autonomous Region(2021D01C201); Intramural Project of People′s Hospital of Xinjiang Uygur Autonomous Region (20200104)

Abstract: 【Abstract】 Objective To investigate the effect of the methyltransferase inhibitor azacitidine (5-azaC) on the expression of homeobox A9 (HOXA9) gene in, as well as proliferation, invasion and migration of A375 cells. Methods In vitro cultured A375 cells were treated with 5-azaC at various concentrations of 1, 5, 10 and 20 μmol/L, while routinely cultured A375 cells receiving no drug intervention served as control group. Methylation-specific PCR was performed to analyze methylation status of the HOXA9 gene promoter region after the treatment with different concentrations of 5-azaC, in order to screen the optimal concentration of 5-azaC for following experiments. Cell counting kit-8 (CCK8) assay was conducted to evaluate the proliferation of A375 cells, Transwell and wound healing assays were performed to estimate the invasion and migration of A375 cells, and real-time fluorescence-based quantitative PCR (qRT-PCR) and Western blot analysis were conducted to determine the mRNA and protein expression of HOXA9 in A375 cells after 5-azaC treatment. Two-independent-sample t test was used for comparisons between two groups. Results Methylation was observed in the HOXA9 gene promoter region in A375 cells in the control group. After 5-azaC treatment, methylated and unmethylated states coexisted in the HOXA9 gene promoter region in A375 cells, and the higher the concentration of 5-azaC, the higher the degree of demethylation of the HOXA9 gene. Therefore, 20 μmol/L 5-azaC was selected to treat A375 cells for 72 hours, which served as 5-azaC treatment group in subsequent experiments. Compared with the control group, the 5-azaC treatment group showed significantly decreased cellular proliferative ability(72.46% ± 2.19% vs. 100%, t = 28.09, P < 0.001), significantly decreased number of invasive cells (242.70 ± 29.19 vs. 466.00 ± 22.65, t = 10.47, P < 0.001), significantly decreased migratory ability (27.56% ± 2.74% vs. 35.69% ± 2.50%, t = 3.79, P = 0.019), significantly increased HOXA9 mRNA expression (1.73 ± 0.28 vs. 1.01 ± 0.15, t = 3.93, P = 0.017), and significantly increased HOXA9 protein expression (0.62 ± 0.03 vs. 0.50 ± 0.01, t = 3.82, P = 0.019). Conclusion 5-azaC can inhibit the proliferative, invasive and migratory ability of A375 melanoma cells, and one of the possible mechanisms underlying this process may be that 5-azaC reverses the methylation in the HOXA9 gene promoter region, activates HOXA9 gene expression, and participates in the regulation of biological behaviors of melanoma cells.

Key words: Melanoma, DNA methylation, Hypomethylation, HOXA9, Azacitidine, A375 cells